Credit rating agency, India Ratings and Research (Ind-Ra) in its latest report has showed the 6.6% yoy revenue growth in India’s pharmaceutical market (IPM) during November 2021, led by improving growth trends in chronic therapies, namely cardiac 6% yoy (October 2021: down 1% yoy) and anti-diabetic 6% yoy (October 2021: up 1% yoy ).
The report further noted that acute therapies namely gastro-intestinal, respiratory and pain/analgesics continued to witness strong growth, aided by the low base impact. During November 2021, volumes were flat yoy (October 2021: declined 1.6% yoy), while price growth was 5.4% (5.3%) and new products launches were 1.2% (1.4%), driven by acute therapy products.
According to the report, acute therapies such as gastro, respiratory and pain/analgesics witnessed sales growth of 13.1% yoy, 16.3% yoy and 17.3% yoy respectively. Growth improvement was observed in chronic therapies during the month, with cardiac growing 6.3% yoy and anti-diabetic reporting 6.0% yoy growth.
